[Zanamivir, oseltamivir].
Kashiwagi
Seizaburo
S
Fukuoka Red Cross Blood Center.
D000081:Acetamides / Q000008:administration & dosage / Q000493:pharmacokinetics; D000998:Antiviral Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D001682:Biological Availability; D002986:Clinical Trials as Topic; D016903:Drug Monitoring; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics; D006146:Guanidines; D006207:Half-Life; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy*; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D053139:Oseltamivir; D011714:Pyrans; D012794:Sialic Acids / Q000008:administration & dosage / Q000493:pharmacokinetics; D053243:Zanamivir
D000081:Acetamides; D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D053139:Oseltamivir; D009439:Neuraminidase; D053243:Zanamivir